There has been expectation that the antibody could be made available at a discount to Merck & Co's PD-1 inhibitor Keytruda (pembrolizumab), which dominates first-line NSCLC treatment, offering an ...
Under Indaptus' clinical supply agreement with BeiGene, the New York biotechnology company plans to advance human clinical evaluation of its cancer treatment -- called Decoy20, which is being studied ...
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say ...
Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration ...
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
News Medical on MSN5d
New combination treatment authorized for unresectable urothelial cancer patientsAstellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in ...
Promising results from the anti–LAG-3/anti–PD-1 combo for melanoma, FDA approval of inavolisib for PIK3CA-mutant breast cancer, significant survival benefits from talazoparib and enzalutamide in ...
The drugmaker found a fixed-dose combination of Keytruda and an anti-LAG-3 antibody failed to improve ... setting has fueled interest in combining PD-1/L1 inhibition with other mechanisms of ...
Gilead is withdrawing the accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for metastatic urothelial cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback